| abstract |
The present disclosure relates to HCMV ribonucleic acid (RNA) vaccines and methods of using the vaccines and compositions comprising the vaccines. Various human cytomegalovirus amino acid sequences encompassed by this disclosure are shown in Tables 1, 2 and 6. The RNA vaccine provided herein comprises at least one RNA polynucleotide encoding at least one of the HCMV proteins provided in Tables 1, 2, or 6, or a fragment, homolog (eg, at least 80%, 85%, 90%, 95%, 98% or 99% identity) or derivatives. [Selection] Figure 6 |